Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease.

Details

Serval ID
serval:BIB_8BDEC3D75429
Type
Article: article from journal or magazin.
Collection
Publications
Title
Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease.
Journal
Journal of neurology, neurosurgery, and psychiatry
Author(s)
Ribi C., Sztajzel R., Delavelle J., Chizzolini C.
ISSN
0022-3050 (Print)
ISSN-L
0022-3050
Publication state
Published
Issued date
12/2005
Peer-reviewed
Oui
Volume
76
Number
12
Pages
1733-1735
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Abstract
Behçet disease is a chronic relapsing inflammatory condition, predominantly affecting young adults, characterised by recurrent bipolar aphtae and systemic manifestations for which tumour necrosis factor (TNF) alpha blockade has recently emerged as an effective treatment. We report the case of a patient presenting with mucocutaneous and ocular manifestations who in the course of his disease developed CNS parenchymal involvement. While being treated with pulsed cyclophosphamide and corticosteroids, he suffered a relapse of his CNS involvement that was efficaciously controlled by infliximab. No disease activity was observed during a full year of TNF blockade, associated with azathioprine, colchicine, and corticosteroids. However, 7 months after the last administration of infliximab and still under immunosuppressant agents, CNS lesions recurred. Infliximab was successfully reintroduced and since continued with no side effects. The sequence of events observed in this patient suggests that TNF blockade is efficacious in suppressing neuro-Behçet disease and once introduced should be maintained for a prolonged period of time.
Keywords
Adult, Antibodies, Monoclonal/therapeutic use, Antirheumatic Agents/therapeutic use, Behcet Syndrome/drug therapy, Behcet Syndrome/immunology, Behcet Syndrome/pathology, Cyclophosphamide/pharmacology, Cyclophosphamide/therapeutic use, Humans, Immunosuppressive Agents/pharmacology, Immunosuppressive Agents/therapeutic use, Infliximab, Male, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Web of science
Open Access
Yes
Create date
01/07/2020 11:49
Last modification date
02/07/2020 9:32
Usage data